Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter randomized phase III study comparing docetaxel with carboplatin versus docetaxel single agent as second line treatment in patients with non-small cell lung cancer (NSCLC).

Trial Profile

Multicenter randomized phase III study comparing docetaxel with carboplatin versus docetaxel single agent as second line treatment in patients with non-small cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2010

At a glance

  • Drugs Docetaxel (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2009 Actual patient numbers (135) added as reported by ClinicalTrials.gov.
    • 20 Jul 2008 Status changed recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jul 2008 Actual end date is now 1 May 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top